Skip to main content
. 2015 Jul;22(7):336–343. doi: 10.1101/lm.038083.115

Figure 1.

Figure 1.

TTC analysis of infarct size 48 h after MCAO. The GSK-3β inhibitor was administered at the onset of stroke with a second dose at 24 h after stroke. (A) Representative TTC stained coronal sections showing neuroprotective effects of GSK-3β inhibition compared with vehicle (white = infarcted area; red = viable tissue). (B) Quantification data of infarct analysis Vehicle treated (n = 10); GSK-3β inhibitor VIII (n = 11); (*) P < 0.05. Error bars represent SEM.